Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01HL172827-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
The primary objective is to examine the efficacy of an mHealth adherence intervention (Asthma Ctrl) on adherence to daily inhaled corticosteroids as measured by electronically monitored adherence in adolescents with asthma. The secondary objective is to compare the effectiveness of three intervention strategies: 1. asthma management app (control); 2. Asthma Ctrl; 3. Asthma Ctrl+ on adherence, lung function, and health care utilization at post-intervention and 1- and 6-month follow-up. The third objective is to explore and contrast different challenges and combinations of challenges to identify which are most impactful in determining response to the three intervention strategies.
Our goal is to evaluate our promising mHealth intervention (Asthma Ctrl) that is easily accessible and tailored based on adherence barriers and to examine predictors of treatment response. In this multi-site R01 with Children's Hospital Colorado, the study investigators will conduct a 2-stage sequential, multiple assignment, randomized trial (SMART) to evaluate the effectiveness of our mHealth intervention strategies for improving adherence to daily inhaled corticosteroids in adolescents with asthma. Following a baseline period, adolescents will be randomized to a mHealth asthma management app (control group) or Asthma Ctrl, a text-messaging intervention providing adherence feedback based on adherence monitoring (treatment) for SMART Stage 1. Participants will be excluded from the study if they have an adherence that is >68%. For SMART Stage 2, adolescents randomized to the treatment group who demonstrate non-adherence (≤68% adherence; non-response) will undergo a second randomization to receive either 1) continued Asthma Ctrl (text messaging) or 2) Asthma Ctrl+ (Asthma Ctrl augmented with a problem-solving intervention delivered via telehealth). Thus, there are three intervention strategies that will be tested in this SMART: #1 control condition, #2 treatment, and #3 adapted treatment after Stage 2 and at follow-up (1 and 6 months). This innovative SMART design will address objectives described in the brief summary.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Active Comparator | Participants will receive access to an asthma management application providing education and automated reminders |
|
| Asthma Ctrl | Experimental | Participants will receive the Asthma Ctrl intervention |
|
| Asthma Ctrl+ | Experimental | Participants will receive the Asthma Ctrl+ intervention |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Asthma Ctrl | Behavioral | Individualized adherence feedback via text messaging intervention based on real-time adherence monitoring |
|
| Measure | Description | Time Frame |
|---|---|---|
| Electronically Monitored Controller Medication Adherence | Monthly adherence rates will be calculated by dividing the number of doses recorded by the electronic monitor by the total number of prescribed doses; the rate is then multiplied by 100 to determine the percentage. For patients prescribed Single Maintenance and Reliever Therapy, per the new asthma guidelines, the study investigators will assume that initial doses taken are for prevention and adherence will be capped at 100%. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Composite Asthma Severity Index (CASI) | A weighted score comprised of:
The CASI score, ranging from 0 to 20 points, includes 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. The CASI is designed for children and adults ages 6 and older. A CASI score in the range of 0 to 3 indicates low severity. A CASI score greater than 3 may indicate medium to high asthma severity. |
| Measure | Description | Time Frame |
|---|---|---|
| Demographic Questionnaire | Adolescents and caregivers will complete a questionnaire to collect information about demographics. | Baseline |
| Hardship questionnaire | Adolescents and caregivers will complete a 19-item validated questionnaire designed to capture current hardships. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rachelle R Ramsey | Contact | 513-803-8348 | rachelle.ramsey@cchmc.org |
| Name | Affiliation | Role |
|---|---|---|
| Rachelle R Ramsey | Children's Hospital Medical Center, Cincinnati | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado AMC | Aurora | Colorado | 80262 | United States |
Sufficient data from this project will be preserved to enable sharing via BioLINCC. The study investigators will share summary data (a less detailed data table) with data that is of sufficient quality to validate and replicate research findings described in the Aims.
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Nov 19, 2025 | Mar 26, 2026 | ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Sequential, multiple assignment, randomized trial
Not provided
Not provided
Not provided
| Asthma Ctrl+ | Behavioral | Interventions described in Asthma Ctrl with problem-solving skills training via four telehealth sessions to occur every other week. |
|
| Control | Behavioral | Asthma management application providing education and automated reminders |
|
| Baseline assessment and then once a month for 12 months |
| Asthma Control: Asthma Control Test (ACT) | Five-item adolescent self-report, 4-week recall of frequency of asthma symptoms, use of rescue medications, effect of asthma on daily functioning, perception of asthma control. Items are rated using a 5-point scale. The total score ranges from 5 to 25. A score of 19 or less indicates that asthma may not be well controlled, signaling the need for a review with a healthcare provide | Baseline assessment and then once a month for 12 months |
| Lung Function | Mobile spirometry to capture Forced Vital Capacity (FVC) | Baseline and then once a month for 12 months |
| Lung Function | Mobile Spirometry to capture Forced Expiratory Volume in 1 second (FEV1) | Baseline and then once a month for 12 months. |
| Lung Function | Mobile spirometry to capture Ration of Forced Expiratory Volume to Forced Vital Capacity (FEV1/FVC) | Baseline and then once a month for 12 months |
| Lung Function | Mobile Spirometry to capture Forced Expiratory Flow (FEF) | Baseline and then once a month for 12 months |
| Healthcare Utilization | Patients and caregivers will self-report the occurrence of asthma-related emergency department and urgent care visits, hospital admissions, and ICU admissions in the past month. Study staff will also review the patient's medical chart for the above information as well as asthma-intubation. | Baseline assessment and then once a month for 12 months. |
| Asthma Exacerbations | Adolescents will provide a two-week recall of their use of oral steroids to treat an exacerbation. Study staff will also review the medical chart for this information. | Baseline assessment and then once a month for 12 months. |
| Baseline assessment and then at 6 months and 12 months |
| Asthma Knowledge | Adolescents will complete a 13-item a questionnaire assessing the extent to which they agree with facts or information about asthma to provide a measure of health beliefs. | Baseline assessment and then at 6 months and 12 months |
| Adolescent Medication Barriers Scale (AMBS) | 16 (adolescent) item report assessing perceived barriers to treatment adherence using a 5-point Likert scale from 1 ("strongly disagree") to 5 ("strongly agree"). Higher scores on the AMBS are linked to poorer adherence and increased medical complications. | Baseline assessment and then at 6 months and 12 months. |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | United States |
|
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |